AstraZeneca , Merck Announced LYNPARZA Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer at ESMO 2019
Charles Gross